Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
ConclusionIf proven to have translational value, these observations would suggest thatCNS/bloodDER may be a key differentiator for siponimod over fingolimod for clinical efficacy in PMS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 17, 2023 Category: Neurology Source Type: research

Intravenous Immunoglobulin Initiation in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims-based Cohort Study
ConclusionA heavy burden of symptoms, comorbidities, and diagnostic testing exists in patients with CIDP initiating IVIG. Characteristics of patients with CIDP initiating different IVIG products are well balanced, suggesting an absence of clinical or demographic determinants underlying IVIG selection. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 17, 2023 Category: Neurology Source Type: research

Predicting the Societal Value of Lecanemab in Early Alzheimer ’s Disease in Japan: A Patient-Level Simulation
ConclusionThe use of lecanemab plus SoC would improve health and humanistic outcomes with reduced economic burden for patients and caregivers with early AD in Japan. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 15, 2023 Category: Neurology Source Type: research

Genetic Predisposition to Periodontitis and Risk of Migraine: A Two-Sample Mendelian Randomization Study
ConclusionsBased on the results of our MR study, there is no causal relationship between PD and migraines or migraines and PD. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 15, 2023 Category: Neurology Source Type: research

Intravenous Immunoglobulin Treatment Patterns and Outcomes in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A US Claims Database Analysis
ConclusionThis real-world analysis of IVIG treatment patterns and treatment and safety outcomes of patients with CIDP who initiated IVIG highlights the unmet need for improved long-term management. Further research is needed to evaluate the use of functional status measures as endpoints for immunoglobulin treatment effectiveness. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 12, 2023 Category: Neurology Source Type: research

Tailoring Rituximab According to CD27-Positive B-Cell versus CD19-Positive B-Cell Monitoring in Neuromyelitis Optica Spectrum Disorder and MOG-Associated Disease: Results from a Single-Center Study
ConclusionOur findings suggest that in our cohort CD27-positive B-cell-based RTX reinfusion regimen was able to reduce the number of RTX reinfusions relative to CD19-positive B-cell monitoring, with comparable efficacy and safety profile. In order to achieve an even more individualized and effective treatment, the FCGR3A genetic polymorphisms could be evaluated when assessing RTX efficacy. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 11, 2023 Category: Neurology Source Type: research

Effect of Intravenous Thrombolytic Dose of Alteplase on Long-Term Prognosis in Patients with Acute Ischemic Stroke
ConclusionsStandard-dose alteplase treatment reduced the risk of long-term recurrence of AIS after hospital discharge and the alteplase dose was not associated with the long-term risk of death from AIS. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 11, 2023 Category: Neurology Source Type: research

Measuring Overall Severity of Myasthenia Gravis (MG): Evidence for the Added Value of the MG Symptoms PRO
ConclusionThe severity of MG can be reflected in a meaningful continuum underpinned by the MG-specific outcome measures. Only ocular muscle manifestations were shown to reflect a possibly different facet of MG severity. With its modular nature and comprehensive content, the MG Symptoms PRO provides complementary information to the outcome measures widely used in MG.Trial RegistrationClinicalTrials.gov identifier: NCT03052751. (Source: Neurology and Therapy)
Source: Neurology and Therapy - May 11, 2023 Category: Neurology Source Type: research

Publisher Correction: Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients
(Source: Neurology and Therapy)
Source: Neurology and Therapy - May 10, 2023 Category: Neurology Source Type: research

The Alterations of Gut Microbiome and Lipid Metabolism in Patients with Spinal Muscular Atrophy
ConclusionsThe gut microbiome and lipid metabolites differed between the patients with SMA and the control subjects. The altered microbiota may be related with the lipid metabolic disorders in SMA. However, further study is necessary to clarify the mechanism of lipid metabolic disorders and develop management strategies to improve the related complications in SMA. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 27, 2023 Category: Neurology Source Type: research

Safety, Tolerability and Pharmacokinetics of Single-Dose Oral SYHA1402 in Healthy Chinese Subjects
ConclusionSYHA1402 administered as a single dose was well tolerated and safe over the dose range of 25 –800 mg. More than 50% of the unchanged SYHA1402 was excreted in urine within the dose range of 25–100 mg.Trial registrationNCT03988413 (https://www.clinicaltrials.gov/; registration date: 17 June 2019). (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 24, 2023 Category: Neurology Source Type: research

Effect of mTOR Inhibitors in Epilepsy Treatment in Children with Tuberous Sclerosis Complex Under 2 Years of Age
ConclusionPatients with TSC treated with mTOR inhibitors demonstrated better seizure control than individuals without this treatment. Adjunctive pharmacotherapy with mTOR inhibitors appears to have a beneficial effect on epilepsy outcome in young children. Further prospective clinical trials should be conducted to determine the efficacy of mTOR inhibitors on epilepsy in patients with TSC under the age of 2  years. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 21, 2023 Category: Neurology Source Type: research

Optimizing  The Timing of Stereotactic Minimally Invasive Drainage for Hypertensive Intracerebral Hemorrhage
ConclusionsCustomized timing of stereotactic drainage may be superior to conventional fixed timing (within 12  h post-hemorrhage) in reducing post-surgery complications and promoting recovery, which supports the potential use of customized timing of stereotactic minimally invasive drainage as a new convention in clinics. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 18, 2023 Category: Neurology Source Type: research

Efficacy of Dimethyl Fumarate in Young Adults with Relapsing-Remitting Multiple Sclerosis: Analysis of the DEFINE, CONFIRM, and ENDORSE Studies
ConclusionThe data support a favorable benefit-risk profile of DMF in young adults, as evidenced by well-characterized safety, sustained efficacy, and stable PROs.Clinical Trial InformationClinical trials.gov, DEFINE (NCT00420212), CONFIRM (NCT00451451), and ENDORSE (NCT00835770). (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 15, 2023 Category: Neurology Source Type: research

Understanding Barriers Along the Patient Journey in Alzheimer ’s Disease Using Social Media Data
ConclusionThis descriptive analysis of out-of-clinic experiences reflected in AD social media posts found that unwillingness/resistance to seeking care was a key barrier, followed by structural barriers to health care, such as affordability/cost. Insights from the lived experiences of AD stakeholders are valuable and highlight the need to improve the patient journey in AD and ease patient and caregiver burden. (Source: Neurology and Therapy)
Source: Neurology and Therapy - April 15, 2023 Category: Neurology Source Type: research